Chimerix tanks, SEC probes Anavex and KaloBios staggers into bankruptcy

What did you miss during the Christmas break? The short answer: Not much. The last week of the year is usually highlighted by a few last-minute deals that need to be reported ahead of New Year's day. But evidently any big deals in the offing have been reserved for the lead-up to JP Morgan. The news in biotech centered around a few key setbacks and a cleanup on aisle Shkreli. We reported that Chimerix's ($CMRX) lead therapy failed a key Phase III study, which sent its shares into meltdown mode. KaloBios is back on the brink after Martin Shkreli's disastrous rescue attempt, filing for bankruptcy protection. And the small Alzheimer's player Anavex revealed that the SEC is investigating the company, apparently focusing on suspicious trading activity involving their shares.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.